FDA pauses Swedish diabetes company's phase III trial plans

The share price of biotech company Diamyd Medical is falling after the the US Food and Drug Administration postponed its planned phase III trial because of several outstanding questions.
Photo: Diamyd Medical / PR
Photo: Diamyd Medical / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

The US Food and Drug Administration (FDA) has put Diamyd Medical's planned phase III trial under a 'partial clinical hold'.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading